Phaseline

Targets › DDX58

DDX58 (Antiviral innate immune response receptor RIG-I): drug programs, companies and trials

1 program from 1 company in 3 trials: 3 Phase 1; Oncology; next expected readout Aug 2027.

Innate immune receptor that senses cytoplasmic viral nucleic acids and activates a downstream signaling cascade leading to the production of type I interferons and pro-inflammatory cytokines. Forms a ribonucleoprotein complex with viral RNAs on which it homooligomerizes to form filaments. (UniProt, O95786)

Open in Phaseline: the race on DDX58, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Seqker BiosciencesPoly-ICLC (Hiltonol)
TLR3 and RIG-I-like receptor agonist; immune adjuvant
IFIH1, DDX58Phase 1Solid Tumors; Follicular Lymphoma; Lymphocytic LeukemiaAug 2027

Conditions

Solid Tumors (1) Follicular Lymphoma (1) Lymphocytic Leukemia (1)

Modalities

other (1)

Companies

Seqker Biosciences (1)

Related targets

IFIH1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.